[sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
Abstract
Article abstract-We have used in vivo single-photon emission computed tomography (SPECT) of the dopamine transporter with 2 beta-carboxymethoxy-3 beta-(4-iodophenyl)tropane ([sup 123 I] beta-CIT) to investigate striatal dopamine transporter loss in patients with early Parkinson's disease (PD). Striatal uptake of [sup 123 I] beta-CIT was compared in eight early-PD patients with exclusively hemiparkinsonism and eight age- and sex-matched healthy subjects. [sup 123 I] beta-CIT striatal uptake was reduced by approximately 53% contralateral and by 38% ipsilateral to the clinically symptomatic side in the hemi-PD patients, compared with the mean striatal uptake in age- and sex-matched healthy subjects. The relative reduction in [sup 123 I] beta-CIT uptake in the hemi-PD patients was greater in the putamen than in the caudate. These data demonstrate that SPECT imaging of the dopamine transporter with [sup 123 I] beta-CIT can identify patients with PD at the onset of motor symptoms and suggest that this technique also may be useful in identifying individuals with developing dopaminergic pathology before onset of motor symptoms.
NEUROLOGY 1996;46: 231-237
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1.
Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease. Neurology 1991;41(suppl 2):8-13.
2.
McGeer PL, Itagaki S, Akiyama S, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574-576.
3.
Golbe L. The genetics of Parkinson's disease: a reconsideration. Neurology 1990;40:7-16.
4.
Bernbeimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitleberger F. Brain dopamine and the syndromes of Parkinson and Huntington, clinical, morphological, and neurochemical correlates. J Neurol Sci 1973;20:415-455.
5.
Lees AJ. When did Ray Kennedy's Parkinson's disease begin? Mov Disord 1992;7:110-116.
6.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
7.
Hart TS. Paralysis agitans: some clinical observations based on the study of 219 cases at the clinic of Professor M. Allen Starr. J Nerv Ment Dis 1904;31:177.
8.
Watts RL, Mandir AS, Ahn KJ, Juncos JL, Zakers GO, Freeman A. Electrophysiologic analysis of early Parkinson's disease. Neurology 1991;41(suppl 2):44-48.
9.
Nahmias C, Garnett ES, Firnau G, Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985;69:223-230.
10.
Otsuka M, Ichiya Y, Hosokawa S, et al. Striatal blood flow, glucose metabolism, and sup 18 F-Dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 1991;54:898-904.
11.
Brooks DJ, Ibanez V, Sawle G, et al. Differing patterns of sup 18 F-Dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
12.
Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 1993;8:271-277.
13.
Snow BJ, Peppard RF, Guttman M, Calne DB. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. Arch Neurol 1990;47:870-874.
14.
Calne DB, Langston JW, Martin WRW, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248.
15.
Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with sup 18 F-DOPA and positron emission tomography. Neurology 1992;42:1894-1900.
16.
Uhl GR. Neurotransmitter transporters (plus): a promising new gene family. Trends Neurosci 1992;15:265-268.
17.
Leenders K, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
18.
Neumeyer JL, Wang S, Milius RA, et al. [sup 123 I]-2-beta-Carbomethoxy-3-beta-(4-iodophenyl)-tropane (beta-CIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991;34:3144-3146.
19.
Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;9:43-49.
20.
Shaya EK, Scheffel U, Dannals RF, et al. In vivo imaging of dopamine reuptake sites in the primate brain using single pheton emission computed tomography (SPECT) and iodine-123 labeled RTI-55. Synapse 1992;10:169-172.
21.
Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomography imaging of the dopamine transporter with sup 11 C-WIN 35,428 reveals marked decline in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
22.
Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
23.
Brucke T, Asenbaum S, Pozzera A, et al. Dopaminergic nerve cell loss in Parkinson's disease quantified with [sup 123 I] beta-CIT and SPECT correlates with clinical findings [abstract]. Mov Disord 1994;9(suppl 1):120.
24.
Seibyl JP, Marek KL, Smith EO, et al. [sup 123 I] beta-CIT SPECT imaging in idiopathic parkinson's disease: correlation of striatal binding abnormality with disease severity [abstract]. Mov Disord 1994;9(suppl 1):89.
25.
Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-164.
26.
Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
27.
Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Evaluation of the monoamine uptake site ligand [sup 123 I]methyl 3 beta-(4-iodophenyl) tropane-2 beta-carboxylate ([sup 123 I] beta-CIT) in nonhuman primates: pharmacokinetics, biodistribution, and SPECT brain imaging coregistered with MRI. Nucl Med Biol 1993;20:597-606.
28.
Holman BL, Carvalho PA, Zimmerman RE, et al. Brain perfusion SPECT using an annular single crystal camera: initial clinical experience. J Nucl Med 1990;31:1456-1461.
29.
Chang LT. A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci 1987;25:638-643.
30.
Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo [sup 123 I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
31.
Fang J, Yu PH. Effect of L-deprenyl, its structural analogues and some mono-amine oxidase inhibitors on dopamine uptake. Neuropharmacology 1994;33:763-768.
32.
van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporter binding in human striatum with [sup 123 I] beta-CIT SPECT. J Nucl Med (in press).
33.
Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237-239.
34.
Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-764.
35.
Scherman D, Desnons C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989;26:551-557.
36.
Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RJS. Striatal function in normal aging-implications for Parkinson's disease. Ann Neurol 1990;28:799-804.
37.
Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the stratum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
38.
Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
39.
Calne DB. Is idiopathic parkinsonism the consequence of an event or a process? Neurology 1993;44:5-10.
40.
Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994;117:501-507.
41.
Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
42.
Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.
Information & Authors
Information
Published In
Copyright
Copyright 1996 by Advanstar Communications Inc.
Publication History
Published online: January 1, 1996
Published in print: January 1996
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Interhemispheric reactivity of the subthalamic nucleus sustains progressive dopamine neuron loss in asymmetrical parkinsonism, Neurobiology of Disease, 191, (106398), (2024).https://doi.org/10.1016/j.nbd.2023.106398
- Dopaminergic molecular imaging in familial and idiopathic Parkinson's disease, Neuroimaging in Parkinson�s Disease and Related Disorders, (69-104), (2023).https://doi.org/10.1016/B978-0-12-821651-4.00016-6
- Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging, Movement Disorders Clinical Practice, 10, 4, (539-546), (2023).https://doi.org/10.1002/mdc3.13687
- What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?, Neurology, 99, 7_Supplement_1, (61-67), (2022)./doi/10.1212/WNL.0000000000200786
- Detection of Parkinso’s disease using Convolutional Neural Networks and Data Augmentation with SPECT images, 2022 12th International Conference on Computer and Knowledge Engineering (ICCKE), (001-006), (2022).https://doi.org/10.1109/ICCKE57176.2022.9960085
- 99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable, Clinical Nuclear Medicine, 47, 3, (201-208), (2022).https://doi.org/10.1097/RLU.0000000000004063
- Update diagnostische Bildgebung des dopaminergen Systems, Angewandte Nuklearmedizin, 45, 04, (278-285), (2022).https://doi.org/10.1055/a-1712-6250
- A review of diagnostic imaging approaches to assessing Parkinson's disease, Brain Disorders, 6, (100037), (2022).https://doi.org/10.1016/j.dscb.2022.100037
- Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review, International Journal of Molecular Sciences, 22, 20, (11234), (2021).https://doi.org/10.3390/ijms222011234
- Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial, BMC Neurology, 21, 1, (2021).https://doi.org/10.1186/s12883-021-02470-8
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.